Psoriatic Arthritis and Psoriasis Treatment Decision Aid
NCT ID: NCT03737045
Last Updated: 2026-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
37 participants
INTERVENTIONAL
2018-12-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AsseSSing Impact in pSoriatic Treatment
NCT05171270
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis
NCT04915105
Understanding Participation Habits Among Plaque Psoriasis Patients
NCT06338358
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
NCT05908240
Study of Psoriatic Arthritis
NCT00001420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Decision Aid Testing
Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
Decision Aid
Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Decision Aid
Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of psoriasis (as confirmed by dermatologist) or psoriatic arthritis (as confirmed by rheumatologist)
3. Treated at Penn
In addition to the above, for the observation and implementation phases of the study:
4. Initiation of a new psoriasis or psoriatic arthritis treatment
* Biosimilars that have been approved by the FDA and available on the US market will similarly be eligible for participation
* Patients may be taking other traditional DMARDs.
* A washout period is not required.
Exclusion Criteria
2. Youth, under the age of 18 years
3. Patients without psoriasis or psoriatic arthritis
4. Not being treated at a Penn clinic
In addition to the above, for the observation and implementation phases of the study:
5. Not starting or switching to a new medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexis Ogdie-Beatty, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital at the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
831515
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.